Dandan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dandan Yu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 shared publications - Yunfei Chen
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 shared publications - Feng Xue
State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 shared publications - Rongfeng Fu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 shared publications - Huan Dong
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 shared publications - Mankai Ju
State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
2 shared publications
Latest Publications
- Open Access
- 23 July 2025
- Published by Springer Nature in Research Square
A Proteomics-Driven Machine Learning Tool for Distinguishing ET from pre-PMF
Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are phenotypically similar but biologically distinct myeloproliferative neoplasms (MPNs), making accurate diagnosis critical yet challenging. We conducted a retrospective study, including 434 ET and 91 pre-PMF patients. Clinical predictors were evaluated using logistic regression in 440 patients. A subset of 85 patients underwent data-independent acquisition (DIA)–based proteomic profiling of FFPE bone marrow samples. Diagnostic models were developed using clinical, proteomic, and combined features, with performance assessed via nested cross-validation. A 9-protein classifier was constructed using random forest followed by support vector machine–recursive feature elimination (SVM-RFE). The proteomic model achieved superior diagnostic performance compared to the clinical model (AUC = 0.849 vs. 0.499) and was comparable to the combined model (AUC = 0.845). The 9-protein panel showed robust discrimination (AUC = 0.895), with top proteins (ARHGEF19, CAST, SFTPA2) performing well in JAK2V617F⁺ (AUC = 0.971) and CALR⁺ (AUC = 0.768) subsets. Proteomic profiling thus outperforms conventional clinical variables and offers a reproducible, molecular-based tool for distinguishing ET from pre-PMF, with potential utility across molecular subtypes in early-phase MPN diagnosis.
- 23 July 2025
- Published by Springer Nature in Research Square
Open AccessA Proteomics-Driven Machine Learning Tool for Distinguishing ET from pre-PMF
Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are phenotypically similar but biologically distinct myeloproliferative neoplasms (MPNs), making accurate diagnosis critical yet challenging. We conducted a retrospective study, including 434 ET and 91 pre-PMF patients. Clinical predictors were evaluated using logistic regression in 440 patients. A subset of 85 patients underwent data-independent acquisition (DIA)–based proteomic profiling of FFPE bone marrow samples. Diagnostic models were developed using clinical, proteomic, and combined features, with performance assessed via nested cross-validation. A 9-protein classifier was constructed using random forest followed by support vector machine–recursive feature elimination (SVM-RFE). The proteomic model achieved superior diagnostic performance compared to the clinical model (AUC = 0.849 vs. 0.499) and was comparable to the combined model (AUC = 0.845). The 9-protein panel showed robust discrimination (AUC = 0.895), with top proteins (ARHGEF19, CAST, SFTPA2) performing well in JAK2V617F⁺ (AUC = 0.971) and CALR⁺ (AUC = 0.768) subsets. Proteomic profiling thus outperforms conventional clinical variables and offers a reproducible, molecular-based tool for distinguishing ET from pre-PMF, with potential utility across molecular subtypes in early-phase MPN diagnosis.
- Open Access
- 23 August 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (6) , 102554
A single-center study of patients with rare isolated acquired clotting factor deficiencies other than acquired hemophilia A
- 23 August 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (6) , 102554
Open AccessA single-center study of patients with rare isolated acquired clotting factor deficiencies other than acquired hemophilia A
- Open Access
- 17 January 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (1) , 102318
Acquired hemophilia A: a single-center study of 165 patients
- 17 January 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (1) , 102318
Open AccessAcquired hemophilia A: a single-center study of 165 patients
- 15 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1207-1218
Characteristics and outcomes of COVID‐19 in Chinese immune thrombocytopenia patients: A prospective cohort study
The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on the immune system. This is the first and largest study on pre-existing immune thrombocytopenia (ITP) patients infected with COVID-19 in China. We prospectively collected ITP patients infected with COVID-19 enrolled in the National Longitudinal Cohort of Hematological Diseases (NICHE, NCT04645199) and followed up for at least 1 month after infection. One thousand and one hundred forty-eight pre-existing ITP patients were included. Two hundred and twelve (18.5%) patients showed a decrease in the platelet (PLT) count after infection. Forty-seven (4.1%) patients were diagnosed with pneumonia. Risk factors for a decrease in the PLT count included baseline PLT count = 40 years (OR, 2.45; 95% CI, 1.12-5.33; p = 0.02), >= 2 comorbidities (OR, 3.47; 95% CI, 1.63-7.64; p = 0.001), maintenance therapy including TPO-RAs (OR, 2.14; 95% CI, 1.17-3.91; p = 0.01) and immunosuppressants (OR, 3.05; 95% CI, 1.17-7.91; p = 0.02). In this cohort study, we described the characteristics of pre-existing ITP patients infected with COVID-19 and identified several factors associated with poor outcomes.
- 15 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1207-1218
Characteristics and outcomes of COVID‐19 in Chinese immune thrombocytopenia patients: A prospective cohort study
The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on the immune system. This is the first and largest study on pre-existing immune thrombocytopenia (ITP) patients infected with COVID-19 in China. We prospectively collected ITP patients infected with COVID-19 enrolled in the National Longitudinal Cohort of Hematological Diseases (NICHE, NCT04645199) and followed up for at least 1 month after infection. One thousand and one hundred forty-eight pre-existing ITP patients were included. Two hundred and twelve (18.5%) patients showed a decrease in the platelet (PLT) count after infection. Forty-seven (4.1%) patients were diagnosed with pneumonia. Risk factors for a decrease in the PLT count included baseline PLT count = 40 years (OR, 2.45; 95% CI, 1.12-5.33; p = 0.02), >= 2 comorbidities (OR, 3.47; 95% CI, 1.63-7.64; p = 0.001), maintenance therapy including TPO-RAs (OR, 2.14; 95% CI, 1.17-3.91; p = 0.01) and immunosuppressants (OR, 3.05; 95% CI, 1.17-7.91; p = 0.02). In this cohort study, we described the characteristics of pre-existing ITP patients infected with COVID-19 and identified several factors associated with poor outcomes.